Deanol
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Deanol: From an Unspecified Original Indication to Insomnia
One-Sentence Summary
Deanol (DMAE) is a liquid product marketed in the United States. The record lists no original approved indication. The TxGNN model predicts it may be effective for insomnia with a very high score, but 0 clinical trials and 0 publications currently support this direction. It is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 99.87% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 1 (the license number in the record is blank, so it is not a verified NDA number) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available for deanol. Deanol is generally described as a choline precursor, so a cholinergic pathway is a plausible link to sleep regulation. This link is speculative and not verified by the supplied data.
The direction of effect is also uncertain. Increased cholinergic tone is usually associated with arousal and REM modulation, so deanol could even worsen insomnia rather than help it. No original indication is recorded, so we cannot compare the new indication with an established use.
The TxGNN score is very high (rank 4117), but it reflects a knowledge-graph pattern and not clinical proof. Independent confirmation is needed before this prediction is treated as credible.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Not specified | DMAE (Professional Complementary Health Formulas) | Liquid | Not specified |
Safety Considerations
Please refer to the package insert for safety information. No drug interactions were found in the queried data.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on the model score alone (L5). There are no trials or publications, and the mechanism is unverified. The cholinergic hypothesis could point the wrong way for sleep. The product’s safety information is also missing, which blocks safety screening.
To proceed, the following is needed:
- Package insert warnings and contraindications (blocking; needed for safety screening)
- Mechanism of action data (for example, from the DrugBank API) and a clear analysis of the direction of effect on sleep
- A literature and trial search specific to deanol/DMAE and insomnia or sleep
- Confirmation of the product’s regulatory status, since the license number is blank and the product looks like a complementary health formula, not an NDA drug
- Route and formulation compatibility assessment for the new indication
These results are for research reference only and do not constitute medical advice. Repurposing candidates require clinical validation before any application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.